Strategic Funding and Joint-Development
Our Sole Mission:
Providing Risk Capital, Expertise, Resources and
Global Reach for Accelerated Clinical Development
The SFJ Solution:
Capital
- Fund Trials (100%)
- Avoid Dilution
- Execute Large Deals
- Bridge To Readouts
- An Abingworth & Blackstone Company
Expertise
- Multiple Approvals
- US / Japan / China / EU
- Trial Design
- Trial Execution
- World-Class Advisors
Resources
- Global Reach
- Multiple Disciplines
- Incremental Headcount
- CRO Management
- Full Service
Pipeline / Asset Acceleration
- New Indications
- Incremental Assets
- In-Licensing / M&A Support
- Augmented Trial Budget
- Parallel Trials (vs. Sequential)
- Ex-US Approvals
- Fills operational and funding gaps
- Provides bridge to increased ex-U.S. value
- Assumes 100% of clinical development risk
- Augments expertise
- Accelerates follow-on indications
- Tailors payback to financial objectives
SFJ By The Numbers:
Total Deal
Value
$4.5 billion
Total # of
Partnerships
11
# of Oncology Partnerships
6
Year
Founded
2009
Major Market Approvals
17
“SFJ has proven to be a collaborative and transparent partner from the start of our partnership. Their team is extremely knowledgeable, and add immense value well beyond the financial aspect. SFJ has remained a committed partner as we have navigated the regulatory process, with a success-driven mindset.”
— Cedric Francois, CEO
Apellis Pharmaceuticals
Primary Investors
Over $800 Billion
Assets Under Management
$2.5 Billion
Raised in Life Science Funds
SFJ’s Successful Collaborations
2015
Lenvatinib
Eisai
Thyroid Cancer
US Approved
China Approved
Japan Approved
EU Approved
2017
Mylotarg
Pfizer
Myeloid
Leukemia
US Approved
Japan Approved
EU Approved
2017
Inotuzumab
Pfizer
Lymphoblastic
Leukemia
US Approved
Japan Approved
EU Approved
2018
Dacomitinib
Pfizer
Lung Cancer
US Approved
China Approved
Japan Approved
EU Approved
2021
Empaveli
Apellis
PNH
US Approved
EU Approved
Have an asset to develop?
“Working with the SFJ team to design the optimal structure for Apellis was a truly collaborative effort. Together we structured a deal that was honestly transformational for Apellis and a true success for SFJ. They were creative, balancing their obligations with our needs and working with them was a pleasure. I would highly recommend.”
— Tim Sullivan, CFO
Apellis Pharmaceuticals
SFJ’s Recent Biotech Partnerships
APELLIS
Apellis, a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced a novel, risk-sharing collaboration to support the development of APL-2 in hematologic indications with SFJ Pharmaceuticals.
PHASE BIO
PhaseBio, a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, announced a financing and co-development collaboration with SFJ to support the development of PB2452, a reversal agent for the antiplatelet therapy ticagrelor.
NEKTAR
Nektar Therapeutics, a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cancer and auto-immune disease, announced a financing and co-development collaboration with SFJ Pharmaceuticals to support the development of Bempegaldesleukin (BEMPEG).